Abstract
The treatment of brain tumors and neurodegenerative diseases, represents an ongoing challenge. In Central Nervous System (CNS) the achievement of therapeutic concentration of chemical agents is complicated by the presence of distinct set of efflux proteins, such as ATP-Binding Cassette (ABC) transporters localized on the Blood-Brain Barrier (BBB). The activity of ABC transporters seems to be a common mechanism that underlies the poor response of CNS diseases to therapies.
The molecular characterization of Breast Cancer Resistance Protein (BCRP/ABCG2), as an ABC transporter conferring multidrug resistance (MDR), has stimulated many studies to investigate its activity on the BBB, its involvement in physiology and CNS diseases and its role in limiting the delivery of drugs in CNS.
In this review, we highlight the activity and localization of BCRP on the BBB and the action that this efflux pump has on many conventional drugs or latest generation molecules used for the treatment of CNS tumors and other neurodegenerative diseases.
Keywords: BCRP, Blood-Brain Barrier, brain tumors, multidrug resistance, neurodegenerative diseases.
Anti-Cancer Agents in Medicinal Chemistry
Title:Blood-Brain Barrier and Breast Cancer Resistance Protein: A Limit to the Therapy of CNS Tumors and Neurodegenerative Diseases
Volume: 16 Issue: 7
Author(s): Anna Lisa Iorio, Martina da Ros, Ornella Fantappiè, Maurizio Lucchesi, Ludovica Facchini, Alessia Stival, Sabrina Becciani, Milena Guidi, Claudio Favre, Maurizio de Martino, Lorenzo Genitori and Iacopo Sardi
Affiliation:
Keywords: BCRP, Blood-Brain Barrier, brain tumors, multidrug resistance, neurodegenerative diseases.
Abstract: The treatment of brain tumors and neurodegenerative diseases, represents an ongoing challenge. In Central Nervous System (CNS) the achievement of therapeutic concentration of chemical agents is complicated by the presence of distinct set of efflux proteins, such as ATP-Binding Cassette (ABC) transporters localized on the Blood-Brain Barrier (BBB). The activity of ABC transporters seems to be a common mechanism that underlies the poor response of CNS diseases to therapies.
The molecular characterization of Breast Cancer Resistance Protein (BCRP/ABCG2), as an ABC transporter conferring multidrug resistance (MDR), has stimulated many studies to investigate its activity on the BBB, its involvement in physiology and CNS diseases and its role in limiting the delivery of drugs in CNS.
In this review, we highlight the activity and localization of BCRP on the BBB and the action that this efflux pump has on many conventional drugs or latest generation molecules used for the treatment of CNS tumors and other neurodegenerative diseases.
Export Options
About this article
Cite this article as:
Iorio Lisa Anna, Ros da Martina, Fantappiè Ornella, Lucchesi Maurizio, Facchini Ludovica, Stival Alessia, Becciani Sabrina, Guidi Milena, Favre Claudio, Martino de Maurizio, Genitori Lorenzo and Sardi Iacopo, Blood-Brain Barrier and Breast Cancer Resistance Protein: A Limit to the Therapy of CNS Tumors and Neurodegenerative Diseases, Anti-Cancer Agents in Medicinal Chemistry 2016; 16 (7) . https://dx.doi.org/10.2174/1871520616666151120121928
DOI https://dx.doi.org/10.2174/1871520616666151120121928 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Role of natural compounds as anti anti-cancer agents
Cancer is considered the leading cause of worldwide mortality, accounting for nearly 10 million deaths in 2022. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy remains an important approach in treatment o f several types of cancers, even though ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Anti-Tumor Efficacy of Pyrvinium Pamoate Nanoliposomes in an Experimental Model of Melanoma
Anti-Cancer Agents in Medicinal Chemistry Phytochemicals: Potential in Management of Climacteric Neurobiology
Current Pharmaceutical Design Molecular Pathways and Related Target Therapies in Liver Carcinoma
Current Pharmaceutical Design The Role of microRNAs in the Diagnosis and Treatment of Malignant Pleural Mesothelioma - A Short Review
MicroRNA Fragment-based Discovery of Potential Anticancer Lead: Computational and in vitro Studies
Current Computer-Aided Drug Design H3K4 Methylation Status and Lysine Specific Methyltransferase KMT2C Expression Correlate with Prognosis in Lung Adenocarcinoma
Current Molecular Pharmacology Isolation and Characterization of a Trypsin-Chymotrypsin Inhibitor from the Seeds of Green Lentil (Lens culinaris)
Protein & Peptide Letters QSAR Guided Semi-synthesis and <i>In-Vitro</i> Validation of Anticancer Activity in Ursolic Acid Derivatives
Current Topics in Medicinal Chemistry Meet Our Editorial Board Member:
Current Pharmaceutical Design Protein Kinase C-theta Inhibitors: A Novel Therapy for Inflammatory Disorders
Current Pharmaceutical Design Phosphorylation Processes Controlling Aromatase Activity in Br east Cancer: An Update
Mini-Reviews in Medicinal Chemistry Sex Impact on Biomarkers, Pharmacokinetics and Pharmacodynamics
Current Medicinal Chemistry Studying Interactions of Drugs with Cell Membrane Nutrient Transporters: New Frontiers of Proteoliposome Nanotechnology
Current Pharmaceutical Design Clinical Applications of Choline PET/CT in Brain Tumors
Current Pharmaceutical Design The Antiangiogenic and Antitumoral Activity of Titanocene Y* In Vivo
Letters in Drug Design & Discovery Tyrosine Kinases as Molecular Targets to Inhibit Cancer Progression and Metastasis
Current Pharmaceutical Design Self-Assembling Peptide Nanofibrous Hydrogel as a Versatile Drug Delivery Platform
Current Pharmaceutical Design Microwave Facilitated Green Synthesis and Characterization of Acrylamide Grafted Copolymer of Kheri (Acacia chundra) Gum Polysaccharide
The Natural Products Journal Mesenchymal Stem Cells: A New Generation of Therapeutic Agents as Vehicles in Gene Therapy
Current Gene Therapy Polymeric Micelles of Modified Chitosan Block Copolymer as Nanocarrier for Delivery of Paclitaxel
Current Nanomedicine